QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:AMED

Amedisys (AMED) Stock Price, News & Analysis

$94.19
-0.23 (-0.24%)
(As of 02/26/2024 ET)
Today's Range
$94.03
$94.53
50-Day Range
$93.20
$95.90
52-Week Range
$69.36
$96.44
Volume
142,797 shs
Average Volume
257,439 shs
Market Capitalization
$3.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$102.25

Amedisys MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
8.6% Upside
$102.25 Price Target
Short Interest
Bearish
9.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.14mentions of Amedisys in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.93%
From $4.48 to $4.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.38 out of 5 stars

Medical Sector

510th out of 942 stocks

Home Health Care Services Industry

5th out of 7 stocks


AMED stock logo

About Amedisys Stock (NASDAQ:AMED)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Stock Price History

AMED Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CAH Mar 2024 103.000 put
Q4 2023 Blue Owl Capital Corp Earnings Call
Amedisys (AMED) Q4 Earnings Lag Estimates
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Kain Capital-Backed PERA Holdings Hires CEO and CCO
Amedisys (NASDAQ:AMED) Coverage Initiated at StockNews.com
AMED Mar 2024 95.000 put
Amedisys, Inc. (NASDAQ:AMED) Sees Large Growth in Short Interest
AMED Mar 2024 70.000 put
AMED Feb 2024 90.000 call
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/26/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
19,000
Year Founded
1982

Price Target and Rating

Average Stock Price Target
$102.25
High Stock Price Target
$115.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-9,750,000.00
Pretax Margin
1.77%

Debt

Sales & Book Value

Annual Sales
$2.24 billion
Cash Flow
$6.10 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
32,080,000
Market Cap
$3.08 billion
Optionable
Optionable
Beta
0.86

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















AMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Amedisys' shares. Their AMED share price targets range from $81.00 to $115.00. On average, they anticipate the company's share price to reach $102.25 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2024?

Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED shares have decreased by 0.9% and is now trading at $94.19.
View the best growth stocks for 2024 here
.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 2,960,000 shares, an increase of 5.7% from the January 15th total of 2,800,000 shares. Based on an average daily volume of 299,000 shares, the days-to-cover ratio is presently 9.9 days. Currently, 9.3% of the company's stock are sold short.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings results on Wednesday, February, 21st. The health services provider reported $0.94 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.10. The health services provider had revenue of $570.79 million for the quarter, compared to analyst estimates of $566.85 million. Amedisys had a positive trailing twelve-month return on equity of 12.76% and a negative net margin of 0.44%. Amedisys's revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the company earned $1.16 earnings per share.

What ETFs hold Amedisys' stock?
What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.86%), FIL Ltd (4.00%), Alpine Associates Management Inc. (3.90%), Westchester Capital Management LLC (2.70%), Mackenzie Financial Corp (2.69%) and Park West Asset Management LLC (2.49%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMED) was last updated on 2/26/2024 by MarketBeat.com Staff